BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17633995)

  • 1. [Evaluation of serum PSA in brain-dead subjects over the age of 50 before organ harvesting: organ donation and the risk of transmission of prostate cancer. Survey of the transplantation committee of the Association Francaise d'Urologie].
    Salomon L; Feuillu B; Petit J; Sallusto F; Lechevallier E; Eschwege P;
    Prog Urol; 2007 Jun; 17(4):828-31. PubMed ID: 17633995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implication of Tests for Prostate-specific Antigen in Brain-dead Organ Donors.
    Lee GW; Lee JM; Lee WJ; Kim YB; Min YG
    Transplant Proc; 2018; 50(1):20-23. PubMed ID: 29407309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostate cancer screening].
    Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
    Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen in the assessment of organ donors.
    Frutos MA; Daga D; Ruiz P; Jose Mansilla J; Requena MV
    Transplant Proc; 2003 Aug; 35(5):1644-6. PubMed ID: 12962742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen as a predictor of an abnormal digital rectal examination.
    Lui PD; Terris MK; Haney DJ; Constantinou CE; Stamey TA
    Br J Urol; 1994 Sep; 74(3):337-40. PubMed ID: 7524998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
    Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
    Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 1994 May; 151(5):1283-90. PubMed ID: 7512659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Antigen: Nonspecific in Deceased Organ Donors.
    Pabisiak K; Ostrowski M; Kram A; Safranow K; Myślak M; Sieńko J; Sulikowski T; Ciechanowski K
    Transplant Proc; 2016 Jun; 48(5):1374-7. PubMed ID: 27496408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
    Terris MK; Stamey TA
    Br J Urol; 1994 Jan; 73(1):61-4. PubMed ID: 7507783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
    Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy.
    Borghede G; Aldenborg F; Wurzinger E; Johansson KA; Hedelin H
    Br J Urol; 1997 Aug; 80(2):247-55. PubMed ID: 9284197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.